Skip to main content

Table 1 Characteristics of ACS patients readmitted and not readmitted at 6 months

From: A nomogram for predicting the readmission within 6 months after treatment in patients with acute coronary syndrome

Variables

Total (n = 498)

Non-readmission group (n = 415)

Readmission group (n = 83)

Statistics

P

Age, years, Mean ± SD

64.37 ± 10.02

63.97 ± 9.74

66.33 ± 11.17

t=-1.96

0.051

Gender, n (%)

   

χ2 = 2.431

0.119

 Male

370 (74.30)

314 (75.66)

56 (67.47)

  

 Female

128 (25.70)

101 (24.34)

27 (32.53)

  

Height, m, Mean ± SD

1.68 ± 0.08

1.68 ± 0.08

1.66 ± 0.09

t = 1.91

0.057

Weight, kg, Mean ± SD

69.90 ± 11.92

70.24 ± 11.57

68.21 ± 13.46

t = 1.42

0.157

BMI, kg/m2, Mean ± SD

24.72 ± 3.27

24.77 ± 3.25

24.51 ± 3.37

t = 0.66

0.511

Smoking history, n (%)

   

χ2 = 1.262

0.261

 No

260 (52.21)

212 (51.08)

48 (57.83)

  

 Yes

238 (47.79)

203 (48.92)

35 (42.17)

  

Alcohol drinking history, n (%)

   

χ2 = 0.556

0.456

 No

312 (62.65)

257 (61.93)

55 (66.27)

  

 Yes

186 (37.35)

158 (38.07)

28 (33.73)

  

Gensini score, M (Q1, Q3)

40.00 (24.00, 60.00)

40.00 (24.00, 60.00)

39.00 (23.00, 61.00)

Z=-0.299

0.765

ACS type, n (%)

   

χ2 = 13.912

< 0.001

 NSTEMI

76 (15.26)

61 (14.70)

15 (18.07)

  

 STEMI

122 (24.50)

115 (27.71)

7 (8.43)

  

 UA

300 (60.24)

239 (57.59)

61 (73.49)

  

Number of diseased vessels, n (%)

   

χ2 = 1.508

0.470

 One

181 (36.35)

153 (36.87)

28 (33.73)

  

 Two

142 (28.51)

121 (29.16)

21 (25.30)

  

 Three

175 (35.14)

141 (33.98)

34 (40.96)

  

Treatment, n (%)

   

χ2 = 48.454

< 0.001

 PCI

444 (89.16)

388 (93.49)

56 (67.47)

  

 Others a

54 (10.84)

27 (6.51)

27 (32.53)

  

Diabetes mellitus, n (%)

   

χ2 = 3.719

0.054

 No

322 (64.66)

276 (66.51)

46 (55.42)

  

 Yes

176 (35.34)

139 (33.49)

37 (44.58)

  

Hypertension, n (%)

   

χ2 = 5.740

0.017

 No

209 (41.97)

184 (44.34)

25 (30.12)

  

 Yes

289 (58.03)

231 (55.66)

58 (69.88)

  

Comorbidities b, n (%)

   

χ2 = 4.735

0.030

 No

152 (30.52)

135 (32.53)

17 (20.48)

  

 Yes

346 (69.48)

280 (67.47)

66 (79.52)

  

HGB, g/L, Mean ± SD

136.85 ± 17.35

137.36 ± 16.76

134.30 ± 19.98

t = 1.31

0.194

WBC, 109/L, M (Q1, Q3)

7.27 (6.02, 9.16)

7.28 (5.98, 9.34)

7.15 (6.28, 8.70)

Z=-0.590

0.555

PLT, 109/L, Mean ± SD

215.33 ± 57.40

217.07 ± 58.17

206.61 ± 52.84

t = 1.52

0.130

NEUT, 109/L, M (Q1, Q3)

4.42 (3.37, 6.33)

4.41 (3.36, 6.47)

4.62 (3.47, 5.69)

Z=-0.134

0.893

Cr, µmol/L, M (Q1, Q3)

78.00 (68.00, 92.00)

78.00 (68.00, 91.00)

79.00 (67.00, 96.00)

Z = 0.931

0.352

SUA, µmol/L, Mean ± SD

351.96 ± 97.42

346.17 ± 91.58

380.89 ± 118.99

t=-2.51

0.014

TC, mmol/L, M (Q1, Q3)

3.78 (3.13, 4.48)

3.78 (3.18, 4.44)

3.78 (3.04, 4.74)

Z = 0.417

0.677

TG, mmol/L, M (Q1, Q3)

1.41 (0.99, 2.05)

1.41 (0.99, 2.02)

1.51 (1.00, 2.34)

Z = 1.026

0.305

HDL, mmol/L, Mean ± SD

1.01 (0.84, 1.17)

1.01 (0.85, 1.17)

0.97 (0.80, 1.17)

Z=-0.791

0.429

LDL, mmol/L, M (Q1, Q3)

2.28 (1.79, 3.06)

2.29 (1.79, 3.06)

2.23 (1.63, 3.11)

Z=-0.310

0.757

CK-MB, µg/L, M (Q1, Q3)

14.45 (11.20, 30.60)

14.30 (11.00, 34.50)

14.80 (11.50,21.70)

Z=-0.719

0.472

BNP, pg/mL, M (Q1, Q3)

147.00 (58.00, 810.00)

147.00 (59.00, 776.00)

151.00 (57.00,1243.00)

Z = 1.083

0.279

cTnI, ng/ml, M (Q1, Q3)

0.02 (0.01, 0.47)

0.02 (0.01, 0.57)

0.02 (0.01, 0.22)

Z=-0.532

0.595

Mb, ng/ml, M (Q1, Q3)

31.65 (21.00, 64.40)

31.70 (21.00, 66.30)

31.50 (21.00, 59.90)

Z=-0.716

0.474

LVEF, %, n (%)

   

χ2 = 1.376

0.241

 <60

153 (30.72)

123 (29.64)

30 (36.14)

  

 ≥60

345 (69.28)

292 (70.36)

53 (63.86)

  

eGFR, ml/min, M (Q1, Q3)

92.42 (77.15, 106.62)

92.98 (78.76, 106.62)

83.42 (72.65, 110.87)

Z=-1.622

0.105

Length of stay, days, M (Q1, Q3)

7.00 (5.00, 10.00)

7.00 (5.00, 10.00)

8.00 (5.00, 14.00)

Z = 1.271

0.204

Adverse events occurred during hospitalization c, n (%)

   

χ2 = 20.413

< 0.001

 No

515 (93.47)

437 (95.62)

78 (82.98)

  

 Yes

36 (6.53)

20 (4.38)

16 (17.02)

  

Clopidogrel, n (%)

   

χ2 = 0.796

0.372

 No

457 (82.94)

382 (83.59)

75 (79.79)

  

 Yes

94 (17.06)

75 (16.41)

19 (20.21)

  

Calcium channel blockers, n (%)

   

χ2 = 0.021

0.885

 No

431 (78.22)

358 (78.34)

73 (77.66)

  

 Yes

120 (21.78)

99 (21.66)

21 (22.34)

  

ACEI/ARB, n (%)

   

χ2 = 0.113

0.737

 No

435 (78.95)

362 (79.21)

73 (77.66)

  

 Yes

116 (21.05)

95 (20.79)

21 (22.34)

  

Statins, n (%)

   

χ2 = 4.951

0.026

 No

63 (11.43)

46 (10.07)

17 (18.09)

  

 Yes

488 (88.57)

411 (89.93)

77 (81.91)

  

Diuretics, n (%)

   

χ2 = 2.960

0.085

 No

471 (85.48)

396 (86.65)

75 (79.79)

  

 Yes

80 (14.52)

61 (13.35)

19 (20.21)

  
  1. ACS: acute coronary syndrome; SD: standard deviation; BMI: body mass index; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction; UA: unstable angina; PCI: percutaneous coronary intervention; HGB: hemoglobin; WBC: white blood cells; PLT: blood platelet; NEUT: neutrophils; Cr: creatinine; SUA: serum uric acid; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; CK-MB: creatine kinase-MB; BNP: brain natriuretic peptide; cTnI: cardiac troponin I; Mb: myoglobin; LVEF: left ventricular ejection fraction; eGFR: glomerular filtration rate.
  2. a Other treatments include cardiovascular primary prevention, cardiovascular secondary prevention, thrombolysis, and drugs.
  3. b Comorbidities include gout, congestive heart failure, end-stage renal disease, chronic obstructive pulmonary disease, peripheral vascular disease, hypothyroidism, depression, etc.
  4. c Adverse events that occurred during hospitalization include cardiac arrest, coronary dissection, coronary perforation, acute kidney injury, major bleeding, cardiogenic shock, acute respiratory failure, etc.
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us